Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Neurosense Therapeutics Ltd. ( (NRSN) ) is now available.
NeuroSense Therapeutics Ltd. recently completed a pre-New Drug Submission meeting with Health Canada to discuss the potential early approval of its ALS treatment, PrimeC, under the expedited Notice of Compliance with Conditions pathway. The meeting was constructive, and the company is awaiting formal notification on its eligibility to proceed, which could significantly impact its market positioning and operations.
The most recent analyst rating on (NRSN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Underperform.
Neurosense Therapeutics Ltd. faces substantial financial difficulties, including no revenue and negative equity, severely impacting its overall score. Technical indicators are neutral but do not offset financial weaknesses. The valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. operates in the biotechnology industry, focusing on developing treatments for neurodegenerative diseases. The company’s primary product is PrimeC, which is aimed at treating Amyotrophic Lateral Sclerosis (ALS).
Average Trading Volume: 261,385
Technical Sentiment Signal: Buy
Current Market Cap: $52.78M
For an in-depth examination of NRSN stock, go to TipRanks’ Overview page.